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Background: High-risk human papillomavirus type 16 (HPV16) is a risk factor for cervical cancer. Previous studies
suggest that polymorphisms in the E6 gene or the long control region(LCR)of HPV16 may alter the oncogenic
potential of the virus. The aims of this study were to investigate the genetic variations of HPV16 E6 gene and LCR
in isolates from Chinese population and correlation of the E6 and LCR polymorphisms with disease status of
infected patients.
Methods: HPV16 positive endocervical specimens were collected from 304 women living in Northeast of China.
Sequences of E6 gene and LCR were analyzed by PCR-sequencing.
Results: Two lineages were found in the populations, including EUR lineage and As lineage. Based on the HPV16
prototype, the most frequent variation in the E6 gene was T178A/G (48.7%), followed by mutations of G94A (12.2%)
and T350G (9.9%). The rank orders of incidence of E6 variations in amino acid were as follows: D25E (46.3%), L83V
(9.9%) and H78Y (4.3%). Nucleotide variations in LCR were found in all the 304 isolates from HPV16 positive cervical
samples. The most commonly observed LCR variations were the transition replacement G7193T, 7434CIns, G7521A
and 7863ADel (100%). The As lineage was associated with HPV persistent infections and with disease status of ≥CIN2,3.
The EUR lineage variants showed a negative trend of association with the severity of ≥CIN2,3. Among 41 variations
found in LCR, 25 (61.0%) were located at the binding sites for transcription factors. Occurrence of ≥CIN2,3 was
significantly associated with the mutations of R10G/L83V in E6 and the C7294T co-variation in LCR, after adjusting for
ages of infected patients.
Conclusions: Associations between As lineage and HPV persistent infections, and with disease status of ≥CIN2,3, and
an association between the EUR lineage and negative trend of association with the severity of ≥CIN2,3 were found in
this study. An association between a co-variation of R10G/L83V in E6 and C7294T in LCR and an increased risk for
developing CIN-2,3 was found in a HPV16 infected population of Chinese women. These findings indicate that HPV16
polymorphism influences development of CIN-2,3.
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Persistent infections of high-risk human papillomavirus
(HPV) are the necessary causes of cervical cancer. However,
only a minority of women infected with high-risk HPV will
develop persistent infection [1]. Developing risk of cervical
intraepithelial neoplasia grade 2 or 3 (CIN2,3) is affected
by viral, environmental and host factors, which are also
thought to play a mediating role in cervical carcinogenesis
[2]. HPV has coevolved through time with humans into
distinct genotypes [3,4]. In a given type, the HPV genome
is further classified into variants through cumulative
nucleotide variations less than a 5% difference. Epi-
demiological evidence suggests that polymorphism of
HPV genome could contribute to viral pathogenicity
and oncogenicity [4,5]. A better understanding of the asso-
ciation between HPV polymorphism, persistent infection
and risk for developing cervical cancer could help explain
why only a subset of women with HPV infection develop
cervical cancer.
HPV type 16 (HPV16) is the most prevalent high-risk
(HR) type worldwide and is found in the majority of cer-
vical cancer cases [6,7]. The HPV16 genome is about
7,900 bp long and consists of 8 protein-coding genes
(L1, L2, E1, E2, E4, E5, E6, and E7) and 2 non-coding
regions, including the non-coding region (NCR) and
the long control region (LCR) [8]. Proteins encoded by E6
and E7 genes are the major oncoproteins, which are highly
expressed in tumors and are involved in tumorgenesis.
LCR, adjacent to E6 downstream, contains the early
promoter and regulatory elements involved in viral DNA
replication and transcription.
Based principally on LCR sequences, several studies
from Europe and American have suggested that HPV16
variants can influence viral persistence and development
of cervical cancer [9-11]. The aims of this study were to
detect polymorphism of HPV16 E6 gene and LCR in iso-
lates from women without a history of immunosuppression
in northeast China, and to investigate the association of
polymorphisms of HPV16 E6 gene and LCR with per-




Three hundred and four HPV16 positive cervical cytobrush
samples detected with flow-through hybridization
(Hybribio Ltd, Hong Kong) were collected from women ad-
mitted to the Affiliated Shengjing hospital of China medical
university. According to the cytological and histological
evaluations of fresh specimens, cervical disease statuses of
the women were categorized as normal, cervicitis, atypical
squamous cells of undetermined significance (ASCUS), cer-
vical intraepithelial neoplasia grade 1, 2 and 3 (CIN1, CIN2
and CIN3) and cervical cancer (CC). Histopathologicaldiagnosis was completed by a pathologist who was un-
aware of the HPV detection results. Informed consent
was obtained from participation in the study and this
study was approved by the ethics committee of the
Affiliated Shengjing hospital.
Analysis of HPV16 E6 and LCR by PCR-sequencing
To obtain HPV16 E6 and LCR sequences, a half-nested
PCR was performed as that previously described [12].
According to the reference strain (GenBank KO 2718),
the primers used in the amplification were designed as
follows: the forward primer of LCR-F (5’-ACGCAAAAAA
CGTAAGCTG-3’) is located at nucleotide (nt) 7133–7151,
the out backward primer of E6-R (5’-CTTCCCCATTGGT
ACC TGCAG-3’) at nt 875–895 and the inner backward
primer of E6-R-2 (5’-TCCATGCATGATTACAGCTGGG
TT-3’) at nt 547–570. In the first-round PCR, 10–100 ng of
sample DNA was used as a template; in the second-round
reaction, 1μl of the first-round products were used. PCR
was performed in a 9700 Thermal Cycler (Perkin–Elmer
GeneAmp PCR system) with the following parameters for
all the amplification reactions: an initial denaturation at
94°C for 5 min, followed by 30 cycles of 94°C for 45 sec,
50°C for 45 sec and 72°C for 1 min, and a final elongation
at 72°C for 5 min. A negative control reaction without
DNA template was included in all PCR tests.
The size of the PCR products containing HPV16 E6–
LCR sequence was confirmed by gel electrophoresis. The
amplicons were purified using the QIAquick gel extraction
kit (Qiagen Inc, Mississauga, ON). Direct double-stranded
PCR sequencing was performed for the E6-LCR amplicons
using the same primers as in PCR by fluorescent cycle-
sequencing method (BigDye terminator ready reaction kit;
Perkin-Elmer). All amplicons were sequenced at least twice
to exclude Taq-induced errors. Sequences of the amplicons
were aligned by CLUSTAL W (version 1.8). The obtained
sequences were compared to the reference sequence
(GenBank KO 2718) using NCBI BLAST. The HPV16
sequences were classified into respective variant classes as:
prototype (GenBank KO 2718), European (E), Asian (As),
African 1 (Af-1), African 2 (Af-2) and Asian American (AA)
[13-15]. To assess the effects of LCR variations on binding
sites for cellular transcription factors, the TFSEARCH
software was used [16].
Data analysis
The association of HPV16 polymorphisms with persist-
ent infection and developing risks of CIN2,3 or cervical
cancer of women was investigated. Persistent infection
was conceptualized at least two times positive for HPV
detection in a series of samples collected at more than
three visits. The proportion of women infected with
HPV16 prototype was compared between participants with
transient and persistent infection by Fisher’s exact test. In
Table 1 Information about HPV16 infected women
HPV 16-posotive women (%) n=304
Age (years)
Mean ± SD 48.9 ± 11.7
Median 46
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http://www.biomedcentral.com/1471-2407/13/459this study, CIN1 or low-grade squamous intraepithelial
lesion (LSIL) is not considered as a precursor lesion to
cervical cancer but a morphologic consequence of HPV
infection. So, the controls including women without
CIN or with CIN1 and LSIL are designated as <CIN2,3.
After classifying the isolates into variant lineages, the as-
sociation of HPV16 polymorphisms in women with CIN2,3
or cancer (≥CIN2,3) was analyzed. The rate of HPV16 vari-
ants in 167 women with ≥CIN2,3 were compared to that in
137 women with <CIN2,3. The magnitude of the associ-
ations of HPV16 variants with ≥CIN2,3 was assessed by
calculating odds ratios (OR) and respective 95% confi-
dence intervals (CI). The association of HPV16 poly-
morphism in isolates from women with ≥CIN2,3 was
assessed individually for HPV16 each variations. Fisher’s
exact test was used to assess the significance of the dif-
ferences between dichotomous variables, and a Mann–
Whitney test was used to assess the significance of the
differences of age between groups. Unconditional mul-
tiple logistic regression analysis was performed to ob-
tain maximum likelihood estimates of the OR while
controlling for the confounding effects of study site, age
and smoking. Statistical analyses were performed with
STATISTICA version 6 Software (StatSoft, Tulsa, OK).
Results
Information about the studied population is shown in
Table 1. The grade of cervical disease of the 304 partic-
ipants were 95 without squamous intraepithelial lesion
(SIL), 10 low-grade squamous intraepithelial lesion (LSIL)
diagnosed by cytology, and 32 CIN1, 117 CIN2,3 and
50 cancers diagnosed by histopathology. The median
age of the participants was 46 years. Among the popula-
tions, 121 women had never smoked tobacco, 124 had ever
smoked (35 were current smokers) and 59 had unknown
smoking habits.
Genomic polymorphisms of HPV16 E6 and LCR
Tables 2 and 3 display the sites and natures of the variations
found in E6 and LCR in a total of 304 HPV16 positive cer-
vical samples, and the changes in amino acid sequences of
E6 proteins compared to that of the HPV16 prototype. The
results showed that the predominant variant among women
infected with HPV16 was the EUR lineage (62.8%, 191/304),
followed by As (37.2%, 113/304). Among the EUR lineage,
the variants E350G and E131G were seen in 9.9% (30/304)
and 3.0% (9/304) of the 304 women, respectively. Several
variations in E6 and LCR were co-segregated, including
T178G in E6 gene and T7201C, C7270T, A7287C, A7289C,
A7730C, G7842A in LCR, which were observed in 106
isolates (34.9%, 106/304).
Nucleotide variations of HPV16 E6 were found in 92.1%
(280 of 304) of the HPV16 positive cervical samples,
whereas amino acid variations were found in 65.5%(199 of 304). Nucleotide variations of E6 included 4 silent
mutations of G94A, G176A, C215T and T241G and 5 mis-
sense mutations of A131C, T178G/A, C335T, T350G and
A442C, which led to amino acid variations of R10G, D25E,
H78Y, L83V and E113D, respectively. The most frequent
nucleotide variation was T178G/A (49.7%, 151 of 304),
in which T178G was found in 113 strains and T178A
in 38 strains (Table 2). The rank orders of E6 variants in
amino acid were as follows: D25E (49.7%, 151/304), L83V
(9.9%, 30/304), H78Y (4.3%, 13/304), R10G (3.0%, 9/304)
and E113D (2.6%, 8/304).
In LCR, a total of 41 nucleotide variations were detected
in the 304 isolates. The most common LCR variations
were G7193T, 7434CIns, G7521A, 7863ADel, which were
found in 100% of HPV16 isolates. As shown in Table 3, a
total of 13 novel nucleotide variations in LCR were found.
A co-variation of 10 sites, including C7294T, G7319A,
A7326G, T7350A, T7368G, T7503G, A7515C, G7553T,
A7602G and A7740T in LCR was observed in 22 isolates
(7.2%, 22/304).
Table 2 Variations of HPV 16 E6 gene in strains from patients with different grades of cervical lesions
Variation of HPV-16 E6 at nucleotide position (450bp) Grade of Related Cervical lesion









n=304KO2718 G A G T C T C T A
Variation A C/G A A/G T G T G C
EUR _ _ _ _ _ _ _ _ _ 10 5 4 5 24
EUR a _ _ _ _ _ _ _ _ 10 2 18 0 30
EUR _ _ _ _ t _ _ _ _ 10 2 0 0 12
EUR _ _ _ _ _ g _ _ _ 6 10 2 4 22
EUR _ _ a _ _ _ _ _ _ 12 4 1 0 17
EUR _ _ _ _ _ _ _ _ C 5 0 0 0 5
EUR _ _ _ _ _ _ T _ _ 11 2 0 0 13
EUR _ _ _ A _ _ _ _ _ 7 4 17 10 38
EUR a _ _ _ _ _ _ G _ 4 0 0 0 4
EUR a _ _ _ _ _ _ G C 3 0 0 0 3
EUR _ G _ _ _ _ _ G _ 0 1 8 0 9
EUR _ _ _ _ _ _ _ G _ 3 2 9 0 14
As _ c _ G _ _ _ _ _ 6 3 4 19 32
As _ _ _ G _ _ _ _ _ 8 7 54 12 81
AminoAcid substitution _ R10G _ D25E _ _ H78Y L83V E113D
Note: HPV 16 prototype (GenBank accession number KO 2708) was used as the reference. Nucleotide positions in E6 are presented at the top of the table
according to the reference sequence. Amino acid substitutions are indicated under the corresponding amino acidic position. Nucleotide changes are shown by
the corresponding letters. Dashes indicate positions at which no variation was found. Capital letter indicates synonymous mutation; Lower-case character
indicates non-synonymous mutation. E-p,Europen prototype; CC, cervical cancer.
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25 (61.0%) of the 41 variations were located in the binding
sites for transcription factors. The variation of G7193T
resulted in loss of a putative binding site for the cellular
transcription factor SRY. Furthermore, an insertion of
7434C resulted in a new binding site for the cellular tran-
scription factor Oct-1, while a deletion of 7863A resulted in
loss of a binding site for the cellular transcription factor E2.
In the co-variation of 10 sites, the variation of A7515C
resulted in loss of a binding site for the human activator
AP-1, while the variation of A7602G resulted in an addition
of binding site for the cellular transcription factor Oct-1.
Association of HPV16 polymorphisms with persistent
infection
Two lineages were found in the populations, including
EUR lineage and As lineage. The association of HPV16
polymorphisms with persistent HPV infections was inves-
tigated by comparing the proportion of certain variant in
women with persistent (n =168) and transient (n=106)
HPV infections (Table 1). Among the populations infected
by the HPV16 E variant of T350G, 16 women (9.5%, 16/
168, 95% CI 14.8–29.9) were persistent infections and 12
women (11.3%, 12/106, 95% CI 15.5–36.5) were transient
infections. The difference was not statistically significant
(p=0.76). The As lineage being detected in 81 of the 168(48.2%) persistently infected women and 22 of the 106
(20.8%) transiently infected women was associated with
persistent infections (OR 0.3, CI 0.2-0.5).
Association of HPV16 polymorphisms with risk for
developing CIN2,3
The infection rate of women by HPV16 variants were
compared between 137 women with <CIN2,3 (95 without
CIN and 32 with CIN1, 10 with LSIL) and 167 women
with ≥CIN2,3 (117 with CIN2,3 and 50 with cancer). Con-
trolling for study, older women (OR 1.1, 95% CI 1.0–1.2)
and those with a history of smoking (OR 1.0, 95% CI
0.5–2.0) were not at increased risk for developing ≥CIN2,3.
The number of HPV genotypes per sample was similar be-
tween participants with <CIN2,3 (median of two genotypes)
and those with ≥CIN-2,3 (median of three genotypes)
(OR 1.1, 95% CI 0.9–1.4; p=0.34).
The As lineage was more frequent in pre-malignant
and cervical cancer, and showed a statistically signifi-
cant association for disease progression (OR 0.2, 95%
CI, 0.1-0.3; P<0.001). While, the EUR lineage showed a
statistically significant negative trend of association
with the severity of >CIN2,3 (OR5.0, 95% CI, 2.9-8.3;
P<0.001). Individual polymorphism that varies within
lineages may make sense to look at differences between
different disease groups. However, the 350T/G, the 94G/A
Table 3 Variations of HPV 16 LCR in strains from patients with different grades of cervical lesions
Nucleotide variations Transcription
factors
No. of women with cervical different grades of cervical lesions dysplasia
Normal n=95 CIN1/LSIL n=42 CIN2–3 n=117 CC n=50 Total n=304
NG7193T SRY 95 42 117 50 304
T7201C SRY 65 8 17 16 106
T7228A CdxA 17 4 0 8 29
A7238C CdxA 25 4 8 0 37
T7238A RAP1 17 4 0 8 29
C7270T USF 65 8 17 16 106
A7279T USF 0 5 8 4 17
A7287C 65 8 17 16 106
A7289C 51 8 13 8 80
NC7294T CdxA 0 4 8 10 22
NG7319A 0 4 8 10 22
NA7326G 0 4 8 10 22
A7339T SRY 12 4 0 8 24
NT7350A Dfd, S8 0 4 8 10 22
NT7368G CF2-II 0 4 8 10 22
N7434C(Ins) 95 42 117 50 304
C7436T E2 95 42 117 50 304
G7447T 12 4 0 8 24
G7456A 12 4 0 8 24
G7502T CdxA 17 4 4 8 33
NT7503G HSF 0 4 8 10 22
NA7515C AP-1,cap 0 4 8 10 22
G7521A 95 42 117 50 304
NG7553T Sox-5, SRY,HFH-2 0 4 8 10 22
NA7602G P 0 4 8 10 22
T7608C Hb 8 0 4 4 16
G7677A E2F 12 4 0 8 24
G7683A E2F 12 4 0 8 24
T7714G 19 7 2 2 30
A7730C Oct-1 65 8 17 16 106
NA7740T Oct-1 0 4 8 10 22
T7755A 12 4 0 8 24
T7781C cap 25 0 17 0 42
T7841A 12 4 0 0 16
G7842A 65 8 17 16 106
N7863A(Del) 95 42 117 50 304
G7868A 28 0 9 4 34
T7880C CdxA 12 4 0 8 24
A7884C 12 4 0 8 24
G7885A 12 4 0 8 24
C7930T SRY 65 8 17 16 106
Note: HPV 16 prototype (GenBank accession number KO 2718) was used as the reference. Nucleotide positions in LCR are presented according to the reference
sequence. Novel variations are labeled as ‘N’.
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http://www.biomedcentral.com/1471-2407/13/459polymorphism in the EUR lineage and the 131A/C poly-
morphism in the As lineage did not showed any particular
association with comparing relative risk.
Two nonsynonymous variations of A131G (R10G)
and T350G (L83V) were observed in HPV16 E6 gene.
The variations of R10G/L83V occurred in 1 isolate
from the 137 women with < CIN2,3 and 8 isolates from
the 167 women with ≥CIN2,3. Controlling for study site,
age and smoking, detection of the variant R10G/L83V
(OR 4.7, 95% CI 1.0-23.5; p=0.04) was significantly associ-
ated with risk for developing ≥CIN2,3. The C7294T co-
variation in LCR, which include 10 variations, occurred in 4
strains from the 137 women with <CIN2,3 and 18 strains
from the 167 women with ≥CIN2,3, and was significantly
associated with development of ≥CIN2,3 (OR 3.8, 95% CI
0.8-19.6; p=0.03) (Table 4). The association of cervical
diseases with the other variations of transcription factor
binding sites in LCR could not be conducted, because
of the small number of the variations found in cases
with ≥CIN2,3.
Discussion
In the present study, it was examined whether intratype
variations of E6 and LCR may affect persistent infection
and have higher risk for developing cervical disease.
Sequence variations in E6 gene and LCR were found in
304 HPV16 isolates from women with various grades
of cervical lesions. Phylogenetic analysis of HPV16 variants
with respect to the E6 gene and LCR was conducted to
study the local distribution of different HPV16 lineages,
according to the classification of Yamada et al. [14]. In our
study, phylogenetic analysis of the E6 gene showed an
extremely higher prevalence of the As lineage (49.7%),Table 4 Association between HPV16 E6 and LCR gene and CIN
No. of isolates with dise
Variable <CIN2,3 (n = 137) ≥ CIN2,3 (n
Number of HPV types per sample
No. of types (median) 2 3
EUR lineage 113(82.5) 78(46.7)
E-350G/T 13(11.5) 17(21.8)
E-94G/A 17(15.0) 18(23.1)
As lineage 24(17.5) 89(53.3)
As-131A/C 9(37.5) 23(25.9)
E6 variations
Referent variants 84 (61.3) 88 (52.6)
R10G/ L83V 1(0.7) 8(4.8)
LCR variations
Referent variants 137 (100) 167 (100)
Co-variation of C7294Ta 4 (1.5) 18 (10.8)
Note: nd: no data; *:<CIN2,3 vs >CIN2,3; a: Co-variation of C7294T include: C7294T,
and A7740T.followed by E-prototype lineage (36.4%), E350G-lineage
(9.9%), E131G-lineage (3.0%) and Af-1 variant (4.3%).
Different biological behaviors have been previously
proposed for HPV16 infection. In Europe, it was reported
that the frequency of Non-E variants, of the AA variant, in
particular, increases strikingly with severity of lesion in
infected women, suggesting that they could have a more
relevant role in oncogenesis [17,18]. Although the sample
population in a study by Tornesello et al. contains only
one case infected with the AA variant, the result of histo-
logical examination revealed the presence of a carcinoma
in situ [18]. Non-E variants have been demonstrated to as-
sociate with an increased risk of cervical intraepithelial le-
sion, as compared with E variants [10,19]. Additionally, a
higher prevalence of AA variants was found in squamous
cell carcinoma samples than in normal smears [20-22]. In
the study, only two lineages were found in the population,
including EUR lineage and As lineage. Accordance with
previous researches, the association between As lineage
infection and an increased risk of persistent infection was
observed in our study. The As lineage was more frequent
in pre-malignant and cervical cancer, and showed a statisti-
cally significant association for disease progression. While,
the EUR lineage showed a statistically significant negative
trend of association with the severity of >CIN2,3.
HPV16 E6 polymorphisms have been shown, although
inconsistently, to be associated with CIN or cervical cancer
[23,24]. As reported previously, HPV16 molecular variants
did not evolve from random mutational events as variation
sites and combinations of variations were shared by several
isolates and variants [25,26]. In Europe, the variants har-
boring the HPV16 E6 gene substitution of T350G (L83V)
seem to be associated with an increased risk of persistent2/3 in 304 women
ase grade (%) n=304
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[4,24]. However, this finding has not been confirmed in
other European cohorts and in studies conducted in other
parts of the world [22,27]. The biological significance of
the L83V variation in HPV16 remains uncertain [24,28]. In
our study, the alone L83V variation in HPV16 E6 was not
associated with an increased risk of CIN2,3, but together
with R10G, the nonsynonymous variations R10G/L83V
were associated significantly with an increased risk for
developing CIN2,3. It has been demonstrated that amino
acid changes of R10G/L83V can alter the ability of E6 to
bind and degrade p53, induce antiapoptotic signals or alter
their binding affinity with host HLA [5].
HPV16 variants have been refined by the LCR, a variable
non-coding segment of HPV genome [5]. Non-coding
regions are less restricted in their ability to accumulate
and tolerate variations [26]. Polymorphism of HPV16
LCR has been shown to confer a higher risk of developing
persistent HPV infection, CIN2,3 or cancerous anogenital
lesions[25,29]. A variation in the HPV33 LCR at nt 7732,
resulting in loss of a putative binding site for USF, was
found to be associated with CIN 2,3 [30]. As transcription
of HPV oncogenes is under the control of promoter
and enhancer elements in the LCR, variations within
these motifs may alter the replication and transcription
of HPV16 by abolishing, creating or modifying the affinity
of a binding site for a cellular factor [31]. In our study, the
C7294T co-variation in LCR was demonstrated to associate
with risk for developing ≥CIN2,3. Because of the strong
cosegregation of the co-variations of G7193T, 7434CIns,
C7436T, G7521A, and 7863Adel, it is impossible to deter-
mine if each variation in it was individually responsible for
risk for developing CIN2,3. It is predicted that the vari-
ation of A7515C in the C7294T co-variation can result in
loss of a binding site for the human activator AP-1, while
the variation of A7602G result in an addition of binding
site for cellular transcription factor Oct-1. AP-1 is a Jun/
Fos heterodimer complex protein that activates transcrip-
tion of E6 and E7 genes. Mutations in the second binding
site for AP-1 have been shown in vitro to reduce HPV31
transcription to a lesser extent than mutations in the first
binding site [32]. Oct-1 might activate the epithelial-
specific HPV16 enhancer by stabilizing the binding of
a nuclear factor to the composite element, which in
turn results in higher levels of enhancer activity[33].
The increased binding of Oct-1 to the LCR could result
in increased transcriptional level of HPV16. The dele-
tion at nt 7863A in HPV16 LCR will result in loss of a
binding site for the cellular transcription factor E2.
Mutations in the transcription factor E2 binding site have
been shown in vitro to reduce HPV16 transcription [34].
Alternatively, variations in LCR may cosegregate with
variations in HPV genes involved in replication, activa-
tion or transforming capacity of HPV16 genome thatcould be responsible for increased pathogenicity [13]. In
vitro assessment, in which transcription factors can bind
the LCR in any given transcriptional environment, is re-
quired to confirm the predicted effects of LCR variations.
Conclusion
In summary, the finding of this study is that the R10G/
L83V variations in E6 and C7294T co-variation in LCR was
significantly associated with risk for developing ≥CIN2,3.
Whether these associations are explained by a direct effect
of E6 or LCR variations on HPV infection need to be
complemented by functional studies further.
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